Edwards Lifesciences Corp (EW)
As-reported financials and recent SEC filings for Edwards Lifesciences Corp, latest fiscal period FY2025. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About Edwards Lifesciences Corp
Edwards Lifesciences Corp develops and sells medical devices focused on treating structural heart disease. Its main products include transcatheter aortic valve replacement (TAVR) systems, transcatheter mitral and tricuspid therapies (TMTT), and surgical heart valves. The company serves patients with cardiovascular disease through minimally invasive and surgical heart valve repair and replacement technologies.
Snapshot
Fundamentals are from SEC filings. P/E and market cap are derived from recent market prices, refreshed on a rolling basis (typically within the past week).
What changed at Edwards Lifesciences
- Revenue grew 11.5% to $6.1B in FY2025, faster than the 8.6% the year before.
- Operating margin is 20.8% in FY2025, -11.5 pp against 32.3% in FY2021.
- Most recent quarter Q1 FY2026: revenue $1.6B, up 16.7% from Q1 FY2025.
- Free cash flow was $1.3B in FY2025, 22.0% of revenue.
- Net income fell 74.3% to $1.1B in FY2025.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Edwards Lifesciences’s fundamentals sit among the 558 Healthcare companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
Edwards Lifesciences’s FCF margin of 22.0% ranks in the 89th percentile of the 371 Healthcare companies reporting it. Edwards Lifesciences’s operating margin of 20.8% ranks in the 88th percentile of the 397 Healthcare companies reporting it. Edwards Lifesciences’s debt to equity of 0.06 ranks in the 12th percentile of the 243 Healthcare companies reporting it.
No open-market insider buys in the last 90 days; 16 insider sales totaling $7.2M. For context, about 16% of companies in the universe saw any open-market insider buying in the same window. Browse insider activity →
Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Institutional ownership
Held by 4 of the superinvestors we track (plus 6 quant / multi-strat books), based on each investor’s most recent 13F (latest Q1 2026).
| Investor | As of | Position value | Shares | Change |
|---|---|---|---|---|
| AQR Capital Managementquant | Q1 2026 | $157.1M | 2.0M | Reduced |
| Point72 Asset Managementquant | Q1 2026 | $146.3M | 1.8M | Added |
| Millennium Managementquant | Q1 2026 | $143.9M | 1.8M | Reduced |
| Viking Global Investors | Q1 2026 | $87.9M | 1.1M | New |
| Two Sigma Investmentsquant | Q1 2026 | $84.2M | 1.1M | Added |
| Citadel Advisorsquant | Q1 2026 | $41.6M | 519.0K | Reduced |
| Gotham Asset Management | Q1 2026 | $18.4M | 229.8K | Added |
| Bridgewater Associates | Q1 2026 | $13.8M | 171.9K | Added |
| Wedgewood Partners | Q1 2026 | $13.7M | 171.0K | Reduced |
| Renaissance Technologiesquant | Q1 2026 | $2.3M | 29.0K | New |
No longer held by: D. E. Shaw (as of Q1 2026)
From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.
Recent insider activity
Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.
| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
2026-07-27 | Zovighian Bernard JCEO | Sell | 2.9K | $83.93 | $245K |
2026-07-10 | Lippis Daniel J.CVP, TAVR | Sell | 619 | $91.70 | $57K |
2026-06-30 | Lippis Daniel J.CVP, TAVR | Sell | 619 | $91.40 | $57K |
2026-06-17 | Zovighian Bernard JCEO | Sell | 523 | $87.92 | $46K |
2026-05-29 | Dahl Andrew M.SVP, Corporate Controller | Sell | 568 | $86.08 | $49K |
2026-05-27 | BOBO DONALD E JRCVP,Strategy/Corp Development | Sell | 23.1K | $86.42 | $2.0M |
2026-05-22 | Chopra DaveenCVP, TMTT & Surgical | Sell | 1.5K | $84.60 | $127K |
2026-05-18 | Lippis Daniel J.CVP, TAVR | Sell | 620 | $81.14 | $50K |
2026-05-15 filed 2026-05-18 | BOBO DONALD E JRCVP,Strategy/Corp Development | Sell | 10.0K | $82.07 | $818K |
2026-05-15 filed 2026-05-18 | BOBO DONALD E JRCVP,Strategy/Corp Development | Sell | 8.0K | $81.82 | $655K |
2026-05-12 | Zovighian Bernard JCEO | Sell | 35.5K | $77.92 | $2.8M |
2026-05-12 | Zovighian Bernard JCEO | Sell | 845 | $78.40 | $66K |
Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-07-15 | 11.4M | -1.0% | 2.51 |
| 2026-06-30 | 11.5M | -2.8% | 2.11 |
| 2026-06-15 | 11.8M | -3.0% | 2.40 |
| 2026-05-29 | 12.2M | +6.8% | 2.32 |
| 2026-05-15 | 11.4M | +8.1% | 2.54 |
| 2026-04-30 | 10.5M | +12.9% | 1.66 |
| 2026-04-15 | 9.3M | -6.4% | 1.97 |
| 2026-03-31 | 10.0M | -8.9% | 2.27 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Gross profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B |
| Operating income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| Diluted EPS | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full methodology.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $2.94B | $3.05B | $1.13B | $769.0M | $862.8M |
| Current assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B |
| Total assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B |
| Current liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B |
| Long-term debt | $598.3M | $597.7M | $597.0M | $596.3M | $595.7M |
| Total liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B |
| Total equity | $10.34B | $10.06B | $6.72B | $5.81B | $5.84B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full methodology.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $1.60B | $542.3M | $895.8M | $1.22B | $1.73B |
| Capital expenditure | $260.2M | $252.4M | $253.0M | $244.6M | $325.8M |
| Free cash flow | $1.33B | $289.9M | $642.8M | $973.6M | $1.41B |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full methodology.
Quarterly trend (as reported)
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q1 FY2026 | $1.65B | 16.7% | $380.7M | $0.66 |
| Q4 FY2025 | $1.57B | 13.3% | $91.2M | $0.16 |
| Q3 FY2025 | $1.55B | 14.7% | $291.1M | $0.50 |
| Q2 FY2025 | $1.53B | 11.9% | $333.2M | $0.56 |
| Q1 FY2025 | $1.41B | 6.2% | $358.0M | $0.61 |
| Q4 FY2024 | $1.39B | 9.4% | $385.6M | $0.65 |
| Q3 FY2024 | $1.35B | 8.9% | $3.07B | $5.13 |
| Q2 FY2024 | $1.37B | 7.1% | $366.3M | $0.61 |
Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.
Company facts
Recent SEC filings
Largest Healthcare peers
Monitor EW
Get an alert when Edwards Lifesciences files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor EW freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.